Rising cases of cardiovascular disease to fuel blood flow measurement devices market growth

 

Blood flow measurement devices market is estimated to be valued at US$ XX million in 2022 and is expected to exhibit a CAGR of XX% over the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights

Market Overview:

Blood flow measurement devices are instruments that monitor and measure the flow of blood in various organs, veins, and arteries. These devices can be used for both invasive and noninvasive applications. Blood Flow Measurement Devices Market are also used for diagnostic purposes in a variety of medical procedures such as tumor monitoring, intracranial monitoring, gastroenterology, and peripheral vascular diseases.

Competitive Landscape:

Biomedix Inc., Elcat GmBH, Flowtronics Inc., Medtronics Plc, Ace Medicalsm, Cook Medical, Deltex Medical Ltd., D E Hokanson Inc., Compumedics Ltd., and AKW Medicals Inc.

Key Market Drivers:

The increasing number of aging patients and a growing demand for minimally invasive procedures are other factors driving the blood flow measurement devices market growth. This market is also fueled by technological advancements, increasing awareness about blood flow measurement devices, and a growing clinical application of these devices.

The booming geriatric population in countries like India is expected to boost the growth of this market. This population is increasingly susceptible to chronic diseases and is more prone to adopting technology-driven solutions for their treatment. In addition, the availability of specialty care centers is also

Covid-19 Impact Analysis

Blood flow measurement devices industry experienced high demand during Covid-19 pandemic and this is attributed to the increasing cases of covid-19 infection. This has created need for measuring the blood flow measurement devices for monitoring patient condition.

Key Takeaways:

1.     The blood flow measurement devices market is expected to exhibit a CAGR of XX % over the forecast period owing to the rising prevalence of cardiovascular disease and diabetes among population.

2.     North America is expected to witness significant growth over the forecast period owing to the high prevalence of chronic disease, presence of well-established healthcare infrastructure, and growing expenditure in healthcare facilities.